AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use
Sponsor: Massachusetts General Hospital
Trial Details
| Condition | Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder |
| Intervention | Amplification of Positivity - Cannabis Use (AMP-C) |
| Phase | NA |
| Status | Recruiting |
| Participants | 80 |
| Est. Completion | 1 Jan 2028 |
| Last Updated | 20 May 2026 |
Primary Outcome
Change in Depressive Symptoms (Patient Health Questionnaire-9; PHQ-9); Change in Cannabis Use Frequency (Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory; DFAQ-CU); Usability (System Usability Scale; SUS)
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Aged ≥ 18 years * Resides in the United States * Able to read and understand English and willing to provide informed consent/comply with the study protocol * Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9) * Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) * Current elevated anhedonia, as indicated by the PHQ-9 * Interest in receiving treatment for their cannabis use and depression * Meet criteria for current MDD and CUD per the DSM-5 Exclusion Criteria: * History of a psychotic disorder or bipolar disorder type I/II * Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale * Current psychotherapy engagement * Changes in psychotropic medication within six weeks of the start of study
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service